Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Elderly/PS2 Advanced NSCLC (eNERGY)
NCT03351361Phase 3Completed
- Sponsor
- CHU Rennes
- Start
- Feb 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU Rennes. Primary endpoint: Overall Survival at 3 years. Started Feb 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03351361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351361.